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Abstract
Background: Activating mutations in Kit receptor tyrosine kinase or the related platelet-derived growth factor 
receptor (PDGFR) play an important role in the pathogenesis of gastrointestinal stromal tumors (GIST).
Methods: This study investigated the activity of motesanib, an inhibitor of vascular endothelial growth factor receptors 
(VEGFR) 1, 2, and 3; PDGFR; and Kit, against primary activating Kit mutants and mutants associated with secondary 
resistance to imatinib. Single- and double-mutant isoforms of Kit were evaluated for their sensitivity to motesanib or 
imatinib in autophosphorylation assays and in Ba/F3 cell proliferation assays.
Results: Motesanib inhibited Kit autophosphorylation in CHO cell lines expressing primary activating mutations in 
exon 9 (AYins503-504, IC50 = 18 nM) and exon 11 (V560 D, IC50 = 5 nM; Δ552-559, IC50 = 1 nM). Motesanib also 
demonstrated activity against kinase domain mutations conferring imatinib resistance (V560D/V654A, IC50 = 77 nM; 
V560D/T670I, IC50 = 277 nM; Y823 D, IC50 = 64 nM) but failed to inhibit the imatinib-resistant D816V mutant (IC50 > 3000 
nM). Motesanib suppressed the proliferation of Ba/F3 cells expressing Kit mutants with IC50 values in good agreement 
with those observed in the autophosphorylation assays.
Conclusions: In conclusion, our data suggest that motesanib possesses inhibitory activity against primary Kit 
mutations and some imatinib-resistant secondary mutations.
Background
Approximately 85% to 90% of all cases of gastrointestinal
stromal tumors (GIST) are associated with gain-of-func-
tion mutations in the gene KIT [1-4]. A further 5% to 10%
of cases of GIST are associated with activating mutations
in the platelet-derived growth factor receptor alpha
(PDGFRα) gene [1,4,5]. Activating Kit mutations in GIST
occur principally in the extracellular domain, the jux-
tamembrane domain (which regulates receptor dimeriza-
tion), kinase domain I, and kinase domain II (or
activation loop) [1]. Imatinib, a small-molecule inhibitor
of Kit and PDGFRα, represents an effective first-line ther-
apy option for patients with advanced GIST [6]. Imatinib
is a potent inhibitor of wild-type Kit and juxtamembrane
domain Kit mutants, while Kit activation loop mutants
are resistant [1,7]. Secondary imatinib resistance is most
commonly associated with the acquisition of a secondary
mutation in Kit (either in the kinase domain I or the acti-
vation loop) or in PDGFRα [8].
Motesanib is an orally administered small-molecule
antagonist of vascular endothelial growth factor recep-
tors (VEGFR) 1, 2, and 3; PDGFR and Kit [9,10]. In clini-
cal studies, motesanib has shown encouraging efficacy in
the treatment of patients with advanced solid tumors [10-
13]. In biochemical assays, motesanib potently inhibits
the activity of both Kit (50% inhibitory concentration
[IC50] = 8 nM) and PDGFR (IC50 = 84 nM) [9], suggesting
that it may have direct antitumor activity in GIST [14,15].
The aim of this study was to characterize the ability of
motesanib to inhibit the activity of wild-type Kit in vitro
and in vivo, and to investigate differences in the potency
of motesanib and imatinib against clinically important
primary activating Kit mutants and mutants associated
with secondary imatinib resistance. The results suggest that
motesanib has inhibitory activity against primary Kit muta-
tions and some imatinib-resistant secondary mutations.
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Methods
Reagents
Unless specified otherwise all reagents were purchased
from Sigma Aldrich; all cell culture reagents were pur-
chased from Invitrogen (Carlsbad, CA).
In Vivo Hair Depigmentation Assay
Female C57B6 mice (6 to 8 weeks old; 20 to 30 g; Charles
River Laboratories, Wilmington, MA) were anesthetized,
and an area of skin 2 × 2 cm on the right flank was depil-
ated. Oral administration of either 75 mg/kg motesanib
(Amgen Inc., Thousand Oaks, CA) or vehicle (water, pH
2.5) was initiated on the same day as depilation and con-
tinued for 21 days. On day 21, photographs were taken
for assessment of hair depigmentation. The same patch of
skin was depilated again on day 28, and photographs for
assessment of depigmentation were taken on day 35. All
animal experimental procedures were conducted in
accordance with the guidelines of the Amgen Animal
Care and Use Committee and the Association for Assess-
ment and Accreditation of Laboratory Animal Care stan-
dards.
Preparation of Wild-Type and Mutant KIT Constructs
KIT  m u t a n t s  ( T a b l e  1 )  w e r e  i d e n t i f i e d  f r o m  p u b l i s h e d
reports [8] and generated using PCR-based site-directed
mutagenesis. PCR products were cloned into the
pcDNA3.1+ hygro vector or the pDSRα22 vector (Amgen
Inc), gel purified, and then ligated with a common 5' frag-
ment of human wild-type KIT to yield full-length, mutant
constructs in pcDNA3.1+ hygro or pDSRα22 expression
vectors.
Stable Transfection of CHO and Ba/F3 Cells With Wild-Type 
and Mutant KIT
AM-1/D Chinese Hamster Ovary (CHO) cells (Amgen
Inc.) were maintained under standard conditions. Cells
were transfected with wild-type or mutant KIT  using
Lipofectamine2000 and Opti-MEM (Invitrogen) follow-
ing the manufacturer's instructions. Four days after trans-
fection, cells were transferred into selection medium:
Gibco DMEM High Glucose with 10% FBS plus 300 μg/
mL hygromycin (Roche Applied Sciences, Indianapolis,
IN) for cells transfected with pcDNA3.1+ hygro; DMEM
High Glucose with 10% dialyzed FBS for cells transfected
with pDSRα22. Stably transfected CHO cells were
selected 2 weeks later and maintained as described above.
Interleukin 3 (IL-3)-dependent Ba/F3 cells were main-
tained under standard conditions including 3 ng/mL
murine IL-3 (Cat # PMC0035; Invitrogen/BioSource).
Cells were transfected with wild-type or mutant KIT in
the pDSRa22 expression vector along with linearized
pcDNA Neo using the Nucleofector Kit V and a Nucleo-
porator (Lonza; Cologne, Germany) following the manu-
facturer's instructions. Two to 3 days post transfection,
cells were transferred into selection medium (supple-
mented RPMI medium plus 750 μg/mL G418). Stably
transfected Ba/F3 cells were maintained in supplemented
RPMI medium plus 3 ng/mL murine IL-3.
Fluorescence activated cell sorting (FACS) was utilized
to isolate pools of CHO and Ba/F3 cells stably expressing
wild-type and mutant KIT variants. FACS was performed
on a FACS Aria cell sorter (BD Biosciences San Jose, CA),
under sterile conditions using 488 nm laser excitation.
KIT  transfected cells were labeled with the anti-Kit
monoclonal antibody SR1 (prepared at Amgen Inc.; data
on file) followed by incubation with FITC-labeled sec-
ondary anti-mouse IgG antibody (SouthernBiotech, Bir-
mingham, AL). Cells were then resuspended in
Dulbecco's phosphate-buffered saline with 0.5% bovine
serum albumin at a final concentration of 1 × 106 cells per
mL to ensure a constant and viable sorting rate of 5000
cells/sec. Cells transfected with vector control were used
to adjust the baseline instrument settings. Forward and
side scatter gating enabled the exclusion of dead cells and
debris. The top 10% to 15% of Kit-positive cells within the
overall transfected cell population were then isolated to
ensure collection of high-expressing cells. Cells were
Table 1: Clinically Relevant KIT Mutations
KIT Genotype Mutation Type Domain
Primary activating mutations
Δ552-559 Deletion Juxtamembrane domain
V560D Single mutation Juxtamembrane domain
AYins503-504 Insertion Extracellular domain
Secondary imatinib-refractory mutations
D816V Single mutation Activation loop
Y823D Single mutation Activation loop
V560D/V654A Double mutation Juxtamembrane domain/kinase domain I
V560D/T670I Double mutation Juxtamembrane domain/kinase domain ICaenepeel et al. Journal of Experimental & Clinical Cancer Research 2010, 29:96
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sorted directly into 15 mL conical tubes containing the
appropriate growth media. Cell pools were then cultured
and maintained under the respective selection condi-
tions, and were reanalyzed for Kit expression prior to
characterization of Kit autophosphorylation.
Cell-Based Kit Autophosphorylation Assay
CHO cells stably transfected with wild-type or mutant
isoforms of KIT were seeded in a 96-well tissue culture
plate at a density of 2 × 104 cells per well. For stem cell
factor (SCF) characterization experiments, cells were
stimulated with serial dilutions of SCF for varying times.
To determine IC50 values, the cells were treated for 2
hours with single 10-fold serial dilutions of motesanib or
imatinib starting at 3 μM. Cell lines transfected with
wild-type KIT were stimulated for 10 minutes with 100
ng/mL SCF following treatment with motesanib or ima-
tinib. Cell lines transfected with activating KIT mutants
were not stimulated with SCF in IC50 experiments. Cells
were washed with phosphate-buffered saline and lysed in
RIPA buffer (50 mM Tris, pH 7; 150 mM NaCl, 1% Igepal,
0.5% sodium deoxycholate, 0.1% SDS, 300 μM activated
sodium vanadate, 1× protease inhibitor cocktail) for 30
minutes at 4°C with shaking. Cell lysates were added to a
96-well DELFIA microplate (PerkinElmer Inc.) coated
with anti-Kit antibody (1 μg per well; AF332, R&D Sys-
tems, Inc.; Minneapolis, MN) and incubated for 2 hours.
Lysates were then removed and the plate was washed 3
times with DELFIA wash buffer (PerkinElmer Inc.).
Recombinant anti-phosphotyrosine antibody 4G10 (Cat.
# 05-777; Upstate/Millipore, Billerica, MA) was added to
each well (0.1 μg per well) and incubated at room temper-
ature for 1 hour. The plate was then washed 3 times with
DELFIA wash buffer before 0.01 μg of Eu-N1-labeled
anti-mouse antibody (Cat. # AD0124, PerkinElmer Inc.)
was added to each well. The plate was again incubated at
room temperature for 1 hour and then washed 3 times
with DELFIA wash buffer before the signal was detected
by adding DELFIA enhancement buffer (PerkinElmer
Inc.) to each well. Luminescence was measured using a
Victor Model 1420 multilabel counter (PerkinElmer Inc.).
Kit autophosphorylation at each motesanib or imatinib
concentration was expressed as a percentage of the vehi-
cle control (0.2% DMSO).
Ba/F3 Functional Viability Assay
The ability of Kit mutants to act as survival factors was
assessed in Kit-dependent Ba/F3 cells. Ba/F3 cells stably
transfected with various KIT mutants were seeded in a
96-well tissue culture plate at a density of 5 × 103 cells per
well. To determine IC50 values, cells were treated for 24
hours with single 10-fold serial dilutions of motesanib or
imatinib starting at 3 μM (0.1 μM for motesanib-treated
V560 D and Δ552-559 Kit mutants). Cell viability was
assessed by measuring the level of adenosine triphos-
phate using ATPlite assays (PerkinElmer Life Sciences,
Boston, MA). Reconstituted ATPLite 1-step solution was
added to each well followed by incubation with shaking
for 2 minutes. The plate was read on a Victor Model 1420
multilabel counter (PerkinElmer Inc.) under the lumines-
cence setting. Viability at each motesanib or imatinib
concentration was expressed as a percentage of the vehi-
cle control (0.2% DMSO).
Results
In Vitro Inhibition of Wild-Type Kit by Motesanib
Motesanib potently inhibited SCF-induced autophospho-
rylation of Kit in CHO cells stably transfected with the
wild-type KIT gene (IC50 = 36 nM). In comparison, ima-
tinib inhibited wild-type Kit with an IC50 of 165 nM.
Inhibition of Wild-Type Kit Activity in Mice by Motesanib
Hair depigmentation was used as a surrogate marker to
assess the ability of motesanib to inhibit Kit activity in
vivo [16]. Following depilation, female C57B6 mice were
administered either 75 mg/kg motesanib (n = 8) or vehi-
cle (n = 8) twice daily for 21 days. In mice receiving mote-
sanib, hair regrowth was markedly depigmented
compared with mice receiving vehicle (Figure 1). This
effect was reversible. Following the cessation of mote-
sanib treatment on day 21, the mice were depilated again
Figure 1 Effect of treatment with motesanib or vehicle on hair de-
pigmentation, a surrogate marker of Kit activity [16], in female 
C57B6 mice. Anesthetized animals were depilated and immediately 
treated with either vehicle (water; left panels) or motesanib 75 mg/kg 
BID (right panels) for 21 days. On day 21, hair depigmentation was as-
sessed. Depilation was repeated on day 28 and hair depigmentation 
was again assessed on day 35. Representative images from each treat-
ment group for the day-21 and day-35 time points are shown. BID = 
twice daily.
Day 28
Day 21
(Vehicle and
motesanib 
treatment ends)
Motesanib, 
75 mg/kg BID Vehicle
Day 0
Day 35
———  Depilation  ———
———     ——— DepilationCaenepeel et al. Journal of Experimental & Clinical Cancer Research 2010, 29:96
http://www.jeccr.com/content/29/1/96
Page 4 of 8
on day 28. There was no apparent depigmentation of
regrown hair on day 35. Similar results were obtained in
male mice (data not shown).
Characterization of Kit Mutants
Figure 2 summarizes the results from the autophosphory-
lation experiments using CHO cells stably transfected
with the wild-type KIT  gene or various KIT  mutant
genes. Tyrosine phosphorylation of wild-type Kit was
dose-dependent, with the greatest intensity of autophos-
phorylation occurring after a 30 minute incubation of the
cells with 300 ng/mL of SCF. In contrast, tyrosine phos-
phorylation of activated Kit mutants occurred in the
absence of SCF with no further phosphorylation induced
by treatment with SCF.
Activity of Motesanib against Primary Activating Kit 
Mutants
In CHO cells, motesanib inhibited the autophosphoryla-
tion of the primary activating Kit mutants V560 D, Δ552-
559, and AYins503-504 (Table 2; Figure 3B). In each
instance, motesanib was a more potent inhibitor of Kit
autophosphorylation than imatinib. For example, mote-
sanib inhibited the AYins503-504 mutant with an IC50 of
18 nM, whereas imatinib inhibited this mutant with an
IC50 of 84 nM. Interestingly, the IC50 values for inhibition
of these Kit mutants were lower than the IC50 for inhibi-
tion of wild-type Kit by motesanib. Consistent results
were obtained in a functional viability assay utilizing IL-
3-independent growth of Ba/F3 cells (Figure 3C). For
example, when testing the AYins503-504 mutant, the IC50
for motesanib was 11 nM versus 47 nM for imatinib.
Activity of Motesanib against Imatinib-Resistant Kit 
Mutants
Motesanib inhibited the activity of Kit mutants associated
with secondary imatinib resistance. In Kit autophospho-
rylation assays, motesanib inhibited tyrosine phosphory-
lation of the juxtamembrane domain/kinase domain I
double mutants V560D/V654A and V560D/T670I with
IC50 values of 77 nM and 277 nM, respectively. Imatinib
had limited activity against the V560D/V654A mutant
and no activity against the V560D/T670I mutant at con-
centrations of up to 3000 nM (Table 3; Figure 4B). Consis-
tent results were obtained in the Ba/F3 cells expressing
the V560D/V654A and V560D/T670I mutants with
motesanib IC50 values of 91 nM and 180 nM, respectively.
Again, motesanib was a more potent inhibitor of these
mutants than imatinib (Table 3; Figure 4C).
Similarly, motesanib inhibited autophosphorylation of
the imatinib-resistant activation loop mutant Y823 D
(IC50 = 64 nM) more potently than imatinib (IC50 > 3000
nM) (Table 3: Figure 4B). However, neither motesanib
nor imatinib inhibited autophosphorylation of the D816V
mutant (Table 3). Consistent with these results, mote-
sanib inhibited the growth of Ba/F3 cells transfected with
the V560D/V654A, V560D/T670I, or Y823 D mutant
more potently than imatinib. Of note, the IC50 of ima-
tinib against the Y823 D mutant when established in the
functional viability assay was at least 10-fold lower than
the IC50 measured in the autophosphorylation assay. IL-
3-independent Ba/F3 cells expressing the D816V Kit
mutant could not be established.
Discussion
In this study, motesanib was found to be a potent inhibi-
tor of wild-type Kit, both in vitro and in vivo. In a surro-
g a t e  m a r k e r  a s s a y ,  w e  o b s e r v e d  r e v e r s i b l e  h a i r
Figure 2 Effect of stem cell factor (SCF) treatment on tyrosine 
phosphorylation of wild-type Kit and mutant Kit isoforms stably 
expressed in Chinese hamster ovary cells. Chinese hamster ovary 
cells stably transfected with wild-type (WT) or mutant KIT isoforms 
were stimulated with single serial dilutions of stem cell factor, and Kit 
phosphorylation was assessed. For mutant Kit isoforms, data are ex-
pressed as the percentage of vehicle control. For wild-type Kit, data are 
expressed as the percentage of phosphorylation observed following 
stimulation with 300 ng/mL SCF. The results of a single experiment are 
shown.
 
  
  
  
  
   
   
          
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
     
        
          
           
     
     
  
Table 2: Inhibition of the Activity of Wild-Type Kit and 
Primary Activating Kit Mutants by Motesanib and 
Imatinib*
IC50 of Kit 
Autophosphorylation, nM
IC50 of Stably 
Transfected Ba/F3 
Cell Survival, nM
KIT Genotype Motesanib Imatinib Motesanib Imatinib
Wild-type 36 165 - -
V560D 5 18 3 7
Δ552-559 1 5 0.4 1
AYins503-504 18 84 11 47
*In autophosphorylation experiments, means from 2 experiments 
are shown, with the exception of Δ552-559, which was assessed 
once. Viability experiments were performed once.Caenepeel et al. Journal of Experimental & Clinical Cancer Research 2010, 29:96
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depigmentation in mice treated with motesanib 75 mg/kg
twice daily. This dose is comparable to the doses used in
xenograft studies demonstrating antitumor and antian-
giogenic properties of motesanib [9,17]. Kit signaling
plays an important role in the regulation of hair follicle
melanocytes, likely through control of tyrosinase and
tyrosinase-related protein 1 (TRP1) expression [16].
Depigmentation has previously been observed in mice
treated with anti-Kit antibodies [16,18] or with sunitinib
[18]. Importantly, motesanib had inhibitory activity
against Kit mutants associated with GIST and inhibited
these mutants more potently than imatinib and generally
with an IC50 that was less than or similar to the 24-hour
trough concentration of motesanib at therapeutic doses
in humans [10].
Motesanib was a more potent inhibitor of the primary
activating juxtamembrane domain and extracellular
domain Kit mutants V560 D, Δ552-559, and AYins503-
504, compared with imatinib. Importantly, motesanib
also inhibited the activity of an activation loop mutant
(Y823D) associated with imatinib resistance. Imatinib did
not inhibit this mutant at concentrations of up to 3000
nM, suggesting that there are marked differences in how
the two inhibitors interact with Kit. We previously solved
the structure of motesanib bound to the VEGFR2 kinase
domain at 2.2 Å resolution (PDB Accession Code 3EFL)
[19]. This structure superimposes favorably with that of
Kit co-crystallized with imatinib (PDB Accession Code
1T46) [20]. Both inhibitors bind the inactive, auto-inhib-
ited form of the kinases with the backbone of the protein
reorganized into the so-called "DFG-out" conformation.
Based on the structural similarities and the similar poten-
cies of motesanib against VEGFR2 and Kit, we reasoned
that motesanib binds these target kinases in exactly the
same fashion.
Modeling studies suggest that motesanib engages Kit
via three polar interactions and a multitude of van der
Waals contacts (Figure 5). In the context of this study, the
most important of these interactions are those with thre-
onine 670 via a non-classical CH-O pseudo hydrogen
bond and interactions with valine 654 through hydropho-
Figure 3 Inhibition of the activity of wild-type Kit and primary ac-
tivating Kit mutants by motesanib. Autophosphorylation (ex-
pressed as a percentage of vehicle control) of wild-type Kit (panel A) 
and primary activating Kit mutants (panel B) was assessed in stably 
transfected Chinese hamster ovary cells treated for 2 hours with single 
10-fold serial dilutions of motesanib. Representative data from 1 of 2 
experiments are shown. Viability (expressed as the percentage of vehi-
cle control) of Ba/F3 cells expressing the same primary activating Kit 
mutants treated for 24 hours with single 10-fold serial dilutions of 
motesanib was also assessed (panel C). Viability experiments were per-
formed once (representative curves are shown).
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Table 3: Inhibition of the Activity of Kit Mutants Associated 
With Imatinib Resistance by Motesanib and Imatinib*
IC50 of Kit 
Autophosphorylation, nM
IC50 of Stably 
Transfected Ba/F3 
Cell Survival, nM
KIT Genotype Motesanib Imatinib Motesanib Imatinib
V560D/V654A 77 319 91 145
V560D/T670I 277 >3000 180 >3000
Y823D 64 >3000 62 330
D816V >3000 >3000 - -
*In autophosphorylation experiments, means from 2 experiments 
are shown, with the exception of V560D/V654A and D816V, which 
were assessed once. Viability experiments were performed once.Caenepeel et al. Journal of Experimental & Clinical Cancer Research 2010, 29:96
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bic contacts. The fifteen-fold loss of motesanib activity (5
nM versus 77 nM) noted with the V560D/V654A double
mutant, compared with V560 D alone, is rationalized by
the loss of two van der Waals contacts with alanine 654 in
a similar fashion to that described for imatinib [21,22].
Motesanib and imatinib have much diminished activity
against the activation loop mutant (D816V). The D816V
mutant destabilizes the inactivated form of Kit, in a way
that the ability of the protein to adopt the "DFG out"
(inactive) conformation is much reduced or even elimi-
nated; thus, the mutation prevents both motesanib and
imatinib from binding to the ATP pocket [23,24]. The
failure to potently inhibit the D816V mutation is a feature
of Kit inhibitors in the clinic, with the exception for dasa-
tinib [23,25,26], which binds the "DFG in", or activated
form, of the kinase [27]. However, the ability of motesanib
to inhibit the Y823 D mutant suggests that its activity
may not be entirely restricted to an inactive protein con-
formation, or alternatively it may reflect that in contrast
to the D816V mutation, the conformational equilibrium
of the Y823 D mutant is not shifted permanently to the
active conformation.
The data from the present study are of translational rel-
evance, supporting evidence indicating that targeted
therapy molecules with different binding sites and/or
mode of action may be required in the treatment of can-
cers for which mutations are the primary oncogenic
event. A recent study has demonstrated that differences
in the conformational structure of Kit mutants influences
the ability of sunitinib [28], and imatinib to bind and
inhibit receptor autophosphorylation, thus providing a
unique mechanism of drug resistance for each mutant
that is unlikely to be overcome using a single treatment
[23].
Conclusions
In summary, the results of this study demonstrate that
different Kit mutations respond differently to motesanib
or imatinib. This likely reflects differences in the mole-
cules' mode of action. The data also show that motesanib
is active against Kit mutations associated with resistance,
Figure 5 A model of motesanib bound to the active site of Kit ki-
nase derived from a 2.2 Ångstrom resolution crystal structure of 
motesanib bound to the active site of VEGFR2 kinase (PDB code 
2EFL).
Figure 4 Inhibition of the activity of Kit mutants associated with 
secondary imatinib resistance by motesanib. Autophosphorylation 
(expressed as a percentage of vehicle control) of wild-type Kit (panel A) 
and Kit mutants associated with secondary imatinib resistance (panel 
B) was assessed in stably transfected Chinese hamster ovary cells treat-
ed for 2 hours with single 10-fold serial dilutions of motesanib. Repre-
sentative data from 1 of 2 experiments are shown. Viability (expressed 
as the percentage of vehicle control) of Ba/F3 cells expressing the 
same Kit mutants treated for 24 hours with single 10-fold serial dilu-
tions of motesanib was also assessed (panel C; not shown: D816V, 
which had a motesanib IC50 > 3 μM). Viability experiments were per-
formed once and representative curves are shown (D816V was not 
evaluated because Ba/F3 cells expressing this mutant could not be es-
tablished).
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suggesting that it may have clinical utility in the treat-
ment of patients with primary and secondary imatinib-
resistant GIST.
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